Bladder cancer

Current Opinion in Oncology

Volumn 10, Issue 3, 1998, Pages 273-278

  Ozen, Haluk ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; GALLIUM NITRATE; IFOSFAMIDE; METHOTREXATE; PROTEIN P53; RADIOSENSITIZING AGENT; RETINOBLASTOMA PROTEIN; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; BLADDER MUSCLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE; CHROMOSOME 9; CYSTECTOMY; DISEASE COURSE; DNA DAMAGE; DRUG FATALITY; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MITOSIS INDEX; MOLECULAR GENETICS; MUSCLE DISEASE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031860016     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199805000-00016     Document Type: Review

References (26)

1. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994, CA Cancer J Clin 1994, 44:7-26.
2. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH III. Gonzalez-Zulueta M, Nichols PW, Skinner DG, Jones PA: Role of chromosome 9 in human bladder cancer. Cancer Res 1993, 53:4066-4070.
3. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, et al.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788.
4. Simoneau AR, Spruck CH III, Gonzalez-Zulueta M, Gonzalgo ML, Chan •• MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA: Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 1996, 56:5039-5043. This study clearly shows that inactivation of a possible tumor-suppressor gene on 9q may be the earliest step in bladder tumorigenesis.
5. Lee CCR, Yamamoto S, Monmura K, Wanibuchi H, Nishisaka N, Ikemoto S, Nakatani T, Wada S, Kishimoto T, Fukushima S: Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathological features. Cancer 1997, 79:780-789.
6. Shin KY, Kong G, Kim WS, Lee WS, Woo YN, Lee JD: Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997, 75:1788-1792.
7. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331:1259-1264.
8. Ishikawa J, Xu H-J, Hu S-X, Yandell DW, Maeda S, Kamidono S, Benedict WF, Takahashi R: Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 1991, 51:5736-5740.
9. Cordon-Cardo C, Zhang Z-F, Dalbagni G, Drobnjak M, Charytonowicz E, Hu S-X, Xu H-J, Reuter VE, Benedict WF: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997, 57:1217-1221. Patients who were p53-positive or had undectable levels of pRB had more frequent disease progression and a significantly decreased survival rate. If both markers were altered the prognosis was shown to be even worse. This study shows that alterations of p53 and pRB have a cooperative negative effect on prognosis in patients with bladder cancer.
10. Pawinsky A, Sylvester R, Kurth KH, Bouffioux C, Van Der Meijden A, • Parmar MKB: A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996, 156:1934-1941. Adjuvant intravesical chemotherapy has a favorable effect only on duration of disease-free interval. Prophylactic intravesical chemotherapy for patients with Ta and T1 disease has not been shown to decrease progression to muscle invasive stage, however. The drawback of this study is that both arms received intravesical chemotherapy early or during the course of their disease.
11. Cookson MS, Herr HW, Zhang Z-F, Soloway S, Sogani FC, Fair WR: The • treated natural history of high risk superficial bladder cancer: 15 year outcome. J Urol 1997, 158:62-67. This study underscores the fact that patients with high-risk superficial bladder cancer remain at risk for progression and upper tract tumors for long periods even if they were treated with intravesical BCG initially. It must be emphasized that at 15 years follow-up, 37% of this group had died of bladder cancer.
12. Herr HW, Wartinger DD, Fair WR, Oetgen HF: Bacillus-Calmette Guerin therapy for superficial bladder cancer: a 10-year folowup. J Urol 1992, 147:1020-1023.
13. Herr HW: Tumor progression and survival in patients with T1G3 bladder tumors: 15-year outcome. Br J Urol 1997, 80:762-765.
14. Lacombe L, Dalbagni G, Zhang Z-F, Cordon-Cardo C, Fair WR, Herr HW, Reuter VE: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: correlation to clinical outcome. J Clin Oncol 1996, 14:2446-2652. This study shows that T category is more powerful than initial p53 status in predicting disease progression. For those patients who had not responded to BCG, however, post-therapy p53 positivity was found to be the only predictor of progression. Thus, p53 status for nonresponders to BCG may be used as a criterion for identifying patients who need cystectomy.
15. Holmang S, Hedelin H, Borghede G, Johansson SL: Long-term followup of a bladder carcinoma cohort: Questionable value of radical radiotherapy. J Urol 1997, 157:1642-1646.
16. Smith Jr JA, Crawford ED, Paradello JC, Blumenstein B, Herschman BR, Grossman HB, Christie DW: Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy and radical cystectomy versus radical cystectomy alone: A phase III inter-group study. J Urol 1997, 157:805-808,
17. Coppin CHL, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative radiation. J Clin Oncol 1996, 14:2901-2907.
18. Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman •• AL, Shipley WU: Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997, 15:1022-1029. This study has once more elegantly demonstrated the efficacy and safety of chemoradiation and bladder preservation in selected groups of patients with muscle invasive disease Furthermore, the authors defined a subgroup of patients-T2 and no hydronephrosis-who benefit most from this approach.
19. Given RW, Parsons JT, McCarley D, Wajsman Z: Bladder-sparing multimodality treatment of muscle invasive bladder cancer: A five-year follow-up. Urology 1995, 46:499-505.
20. Fossa SD, Sternberg C, Scher HI, Theodore CH, Mead B, Dearney D, Roberts JT, Skovlund E: Survival of patients with advanced urethelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 1996, 74:1655-1659. The long-term survival after cisplatin-based chemotherapy was documented at seven internationally well-known oncological centers. The overall 5-year cancer-specific survival rate was 11%. The good prognostic group in this study was defined as patients with good performance status with disease confined to lymph nodes or patients with T4b disease.
21. Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM: Cisplatin methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urethelium. J Urol 1993, 150:65-69.
22. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsh J, Kelly WK, Scher HI, Bajorin DF: Phase II randomized trial of gallium nitrate plus flourourasil versus methotrexate, vinblastine, doxorubicin and cisplatin in patients with advanced transitional cell carcinoma. J Clin Oncol 1997, 15:2449-2455.
23. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997, 15:1853-1857.
24. Dreicer R, Propert KJ, Roth BJ, Einhorn LH, Loehrer PJ: Vinblastine, ifosfamide and gallium nitrate: an active regimen in patients with advanced carcinoma of the urethelium, Cancer 1997, 79:110-114.
25. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG: p53 and treatment of bladder cancer. Nature 1997, 385:123-125. The authors have previously shown that p53 alterations negatively effect the prognosis. This study incorporates p53 status in their previously reported adjuvant chemotherapy data following cystectomy. The results show that in patients with no altered p53, chemotherapy had no beneficial effect regarding survival and recurrence. These observations lead to speculation that altered p53 status in tumors may increase the sensitivity of tumors to DNA-damaging agents such as doxorubicin and cisplatin.
26. Skinner DG, Daniels JR, Rusell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Groshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991, 145:459-467.